ABSTRACT
Objectives The recent discoveries of phylogenetically confirmed COVID-19 reinfection cases worldwide, together with studies suggesting that antibody titres decrease over time, raise the question of what course the epidemic trajectories may take if immunity were really to be temporary in a significant fraction of the population. The objective of this study is to answer this question.
Methods We construct a ground-up delay differential equation model tailored to incorporate different kinds of immune response. We consider two immune responses here : (a) short-lived immunity of all kinds, and (b) short-lived sterilizing immunity with durable severity-reducing immunity.
Results Multiple wave solutions to the model are manifest for intermediate values of the reproduction number R; interestingly, for sufficiently low as well as sufficiently high R, we find conventional single-wave solutions despite the temporary immunity.
Conclusions The versatility of our model and its very modest demands on computational resources ensure that a set of disease trajectories can be computed virtually on the same day that a new and relevant immune response study is released. Our work can also be used to analyse the disease dynamics after a vaccine is certified for use and information regarding its immune response becomes available.
Highlights
We show a subtle interplay between public health measures and immune response.
We account for different durations of sterilizing and severity-reducing immunity.
Our results prepare us for what might happen with large-scale temporary immunity.
Our model is relevant for predicting disease dynamics after a vaccine is invented.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We have received NO funding for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research does not involve human or animal subjects so no IRB approvals/exemptions required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos